Keynote Financial Services’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.94M Sell
32,025
-267
-0.8% -$15.6K 1.03% 20
2025
Q4
$1.74M Buy
32,292
+130
+0.4% +$6.25K 0.97% 26
2025
Q3
$1.45M Buy
32,162
+43
+0.1% +$2.01K 0.87% 31
2025
Q2
$1.49M Buy
32,119
+293
+0.9% +$14.4K 1% 27
2025
Q1
$1.94M Buy
31,826
+467
+1% +$27.2K 1.39% 16
2024
Q4
$1.77M Buy
31,359
+119
+0.4% +$6.65K 1.36% 15
2024
Q3
$1.62M Buy
31,240
+535
+2% +$25.1K 1.23% 19
2024
Q2
$1.28M Buy
30,705
+2,955
+11% +$132K 1.07% 27
2024
Q1
$1.5M Buy
+27,750
New +$1.41M 1.26% 21

Other funds holding BMY

Keynote Financial Services's BMY Position: Q1 2026 in Review

Keynote Financial Services reduced its Bristol-Myers Squibb (BMY) stake by 0.83% in Q1 2026, selling an estimated $15.6K and leaving 32,025 shares worth $1.94M. The position accounts for 1.03% of the portfolio, ranked #20.

Keynote Financial Services first reported a position in BMY in Q1 2024 and has held it in 9 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Keynote Financial Services held 32,025 shares of Bristol-Myers Squibb worth $1.94M as of Q1 2026.
  • Keynote Financial Services sold 267 Bristol-Myers Squibb shares in Q1 2026, an estimated $15.6K.
  • Bristol-Myers Squibb made up 1.03% of Keynote Financial Services's portfolio in Q1 2026, its #20 holding.
  • Keynote Financial Services first reported a position in Bristol-Myers Squibb in Q1 2024 and has held it in 9 quarters since.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Keynote Financial Services's 13F filing for Q1 2026, filed 13 May 2026.